ProCE Banner Series

The How and Why of Bispecific Antibodies for R/R DLBCL: Best Practices for Exemplary Care

Expert discussion and takeaways for best practices in the use of bispecific antibodies for the management of relapsed/refractory diffuse large B-cell lymphoma.

  AAPA
  | ANCC
Who Should Attend

This program is intended for nurse practitioners, physician associates, clinical nurse specialists, and advanced degree nurses who manage patients with DLBCL treated with bispecific antibodies.

All Events

The How and Why of Bispecific Antibodies for R/R DLBCL: Best Practices for Exemplary Care

Past Events

October

03

2024

12:00 PM - 1:00 PM Central Time (CT)

Virtual

Faculty

ProCE Banner Faculty
Sherry Adkins, MSN, ANP-C, FAAN

Advanced Practice Provider
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas

ProCE Banner Faculty
Kathleen Dorritie, MD

Assistant Professor of Medicine
Division of Hematology Oncology
UPMC, University of Pittsburgh
Pittsburgh, Pennsylvania

Topics

Lymphomas

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Diffuse large B-cell lymphoma (DLBCL).

Target Audience
This program is intended for nurse practitioners, physician associates, clinical nurse specialists, and advanced degree nurses who manage patients with DLBCL treated with bispecific antibodies. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Explain the mechanism of action of novel bispecific antibody therapies vs other anticancer agents and the role of bispecific antibodies in the treatment of DLBCL
  • Design treatment strategies for the use of bispecific antibodies in R/R DLBCL, based on current indications, consensus guidelines, recent key safety and efficacy data, and patient and disease factors
  • Assess patients for eligibility for ongoing clinical trials and for barriers to and disparities in care that may impact outcomes
  • Apply recommendations to mitigate and manage adverse events associated with bispecific antibody treatment in patients with DLBCL

Accreditation

Joint Accreditation Statement

In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour, including 1.0 hour of pharmacotherapy credit.

Physician Associate Continuing Medical Education

Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.

Disclosure of Conflicts of Interest
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to PACE policies.

Acknowledgement

Provided by Partners for Advancing Clinical Education (PACE) in partnership with Clinical Care Options, LLC

Supported by an educational grant from Genmab US, Inc.